Confidential

Market Opportunity
Lifesciences manufacturers require Real-World Data (RWD) to help develop and demonstrate the value of
interventions and diagnostics. Advanced Real-World Data (aRWD) sourced directly from health systems
and academic medical centers provides researchers with a more robust understanding of disease and
treatments, and fuels new insights and evidence that will accelerate development of interventions and
diagnostics.

• New advances in • High cultural and compliance

• Explosion of unharnessed
computational approaches barriers to winning the trust of
health data within health
to extract insights from health system leadership and
system technology
complex data including data stewards
environments
images and genomics
• Demonstrated value
• Rapidly growing adoption
• High cost and complexity proposition for an
of aRWD to support
associated with intermediary that
decision making across
transforming complex professionalizes data curation
the health ecosystem
health data into research and secure, compliant access
data by industry researchers

CuriMeta Solution

CuriMeta is an advanced RWD technology

platform business that harnesses complex
health data and invests to create research
ready products and services with high
explanatory power to accelerate
development of interventions and
diagnostics within the life sciences market

Fast Facts

1. Founding team comprised of industry veterans with over 200 years of cumulative experience in health data, clinical
research, health technology, data science and informatics, and commercial operations
2. Master Data License executed with Washington University in St. Louis and BJC HealthCare provides CuriMeta broad
access to health data from both care delivery and research, as well as the ability to source and curate multi-modal data
sets with exceptionally high explanatory power
3. Series Seed closed July 2022. Washington University in St. Louis and BJC HealthCare are co-lead investors
4. Significant market interest across core verticals: pharma, biotech, medical device, diagnostics, CRO’s and clinical AI

Business Strategy
Initial Therapeutic Areas of
• Guided by our customer’s research imperatives, CuriMeta transforms siloed health Focus including but not limited to:
system data into high-value, therapeutically aligned data lakes that serve as the
• Cardiometabolic
foundation for fit-for-purpose, regulatory-grade datasets
• Focus on augmenting therapeutic data by deploying best-in-class computational • Neurodegenerative

approaches and expert annotation to create computable data from images, • Colorectal Cancer
pathology, and other unstructured data • Breast Cancer
• Source, curate, and deliver high-quality data using advanced privacy preserving • Lung Cancer
practices that represent the leading edge of ethical data sharing, including ‘on • Sepsis
premise’ data access, synthetic data exploration, statistically certified data de-
identification processes, and agnostic tokenization for data linkage
Initial High-Level Metrics
• Attract and collaborate with additional health system partners through a business
model that prioritizes mission alignment, transparency, shared data governance, and • 3M Researchable Patients
access to ‘enhanced’ data to support academic research objectives • 14 Hospitals, including a
Comprehensive Cancer
• Execute IRB approved, non-interventional retrospective and prospective studies using Center (CCC) and Leading
aRWD in support of our customer’s RWE requirements Academic Medical Center

curimeta.com